EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma

Marie Lommen, Jasmin J Weindler, Janina Jablonski, Johannes Rosenbrock, Peter Borchmann, Karolin Behringer, Katrin S Roth, Dominic Ufton, Markus Dietlein, Carsten Kobe, Justin Ferdinandus iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-02 · 53 (3) · 1847-1855

DOI: 10.1007/s00259-025-07569-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 11.10.2025. Verfasst von Marie Lommen und 10 weiteren Autor:innen. Beteiligte Einrichtung: German Hodgkin Study Group, Cologne, Germany. Hauptthemen laut MEDLINE: Quality of Life, Hodgkin Disease, Tumor Burden. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Köln.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Staging with [ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography (PET) is standard of care in classic Hodgkin lymphoma (cHL). Metabolic tumor volume (MTV) is a quantitative biomarker of tumor burden and has been shown to predict treatment response. This study investigates the association between MTV at baseline PET and health-related quality of life (HRQoL) across different disease stages.

Methods

This post-hoc analysis included 441 patients with newly diagnosed cHL and available baseline PET imaging, enrolled in the GHSG trials HD16, HD17, and HD18. MTV was quantified using a fixed threshold of SUV ≥ 4.0 (SUV4.0) via the LifeX Analytics workstation. HRQoL was assessed using the EORTC QLQ-C30 questionnaire at baseline and, for HD18 patients, again at 2-year follow-up. Multiple regression models adjusted for sex, age, and trial/stage were used for statistical analyses.

Results

Higher MTV was associated with higher baseline HRQoL burden across several domains: fatigue (β = 0.14, 95% CI [0.05; 0.24]), dyspnea (β = 0.21, 95% CI [0.11; 0.30]), appetite loss (β = 0.13, 95% CI [0.03; 0.23]), and sleep disturbance (β = 0.12, 95% CI [0.02; 0.22]). In contrast, higher MTV was negatively associated with physical functioning (β = –0.18, 95% CI [–0.27; –0.08]) and global health status (β = –0.15, 95% CI [–0.25; –0.06]). The strongest associations were observed in patients with advanced-stage disease (HD18). At 2-year follow-up in HD18, no associations between MTV at baseline and HRQoL were found, with the exception of pain, which remained the only associated domain (β = 0.15, 95% CI [0.00; 0.30]).

Conclusion

Baseline MTV is strongly associated with HRQoL before therapy in patients with newly diagnosed cHL, particularly in those with advanced-stage disease. Reassuringly, there seems to be no major influence of initial disease burden on HRQoL within the second year of recovery.

Trial registration

ClinicalTrials.gov: HD16 (NCT00736320; first posted August 15, 2008), HD17 (NCT01356680; first posted May 19, 2011), HD18 (NCT00515554; first posted August 13, 2007).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeHodgkin DiseaseTumor BurdenHumansMaleFemaleMiddle AgedAdultPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Aged

Stichwörter der Autor:innen

Hodgkin-LymphomaMTVPETQoLQuality of life

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • German Hodgkin Study Group, Cologne, Germany.
  • Department I of Internal Medicine, and Center for Integrated Oncology, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany.
  • Department for Nuclear Medicine, Faculty of Medicine and University Hospital, Cologne, Germany.
  • Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • German Hodgkin Study Group, Cologne, Germany. justin.ferdinandus@uk-koeln.de.
  • Department I of Internal Medicine, and Center for Integrated Oncology, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany. justin.f…

ORCID-Profile: Justin Ferdinandus

Förderung

  • Universitätsklinikum Köln

Zitieren

APA

Lommen, M., Weindler, J. J., Jablonski, J., Rosenbrock, J., Borchmann, P., Behringer, K., Roth, K. S., Ufton, D., Dietlein, M., Kobe, C., & Ferdinandus, J. (2026). Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 53(3), 1847-1855. https://doi.org/10.1007/s00259-025-07569-5

Vancouver

Lommen M, Weindler JJ, Jablonski J, Rosenbrock J, Borchmann P, Behringer K, et al. Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(3):1847-1855. doi:10.1007/s00259-025-07569-5

BibTeX
@article{Lommen2026,
  author = {Lommen, Marie and Weindler, Jasmin J and Jablonski, Janina and Rosenbrock, Johannes and Borchmann, Peter and Behringer, Karolin and Roth, Katrin S and Ufton, Dominic and Dietlein, Markus and Kobe, Carsten and Ferdinandus, Justin},
  title = {Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {3},
  pages = {1847--1855},
  doi = {10.1007/s00259-025-07569-5}
}
Kostenlos starten →